因塞特 INCY 深 滬
等待開盤 12-24 09:30:00 美东时间
100.91
+0.200
+0.20%
華盛通- 最 高101.71
- 今 開100.50
- 成交量 133.07万股
- 最 低 100.02
- 昨 收 100.71
- 總市值 196.77亿
- 52周最高 109.275
- 市盈率 靜 651.45
- 換手率 0.68%
- 52周最低 53.56
- 委 比 -94.32%
- 總股本 1.95亿
- 歷史最高 153.15
- 量 比 0.50
- 振 幅 1.68%
- 歷史最低 11.76
- 每 手 1
- 風險率 13.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Incyte announces EU approval of Xencor-partnered lymphoma therapy
Incyte (INCY) announced on Wednesday that the European Commission approved a drug regimen containing its Xencor (XNCR)-partnered antibody drug Minjuvi as a late-line option for certain adults with fol...
12-18 00:52
European Commission Approves Incyte's Minjuvi In Combination With Lenalidomide And Rituximab For Relapsed or Refractory Follicular Lymphoma
Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab is the first CD19- and CD20-dual-targeted immunotherapy combination regimen approved for eligible patients in Europe with relapsed or refractory
12-18 00:23
Is Incyte Corp Gaining or Losing Market Support?
Incyte Corp's (NYSE:INCY) short interest as a percent of float has fallen 3.67%...
12-17 00:00
Incyte Board Member Hervé Hoppenot Retires
Incyte ( ($INCY) ) has provided an announcement. On December 10, 2025, Hervé Ho...
12-13 00:57
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
Syndax Pharmaceuticals' Revuforj® (revumenib), a first-in-class menin inhibitor, was awarded "Best New Drug" at the 2025 Scrip Awards, recognizing its groundbreaking science and therapeutic advances in treating relapsed or refractory acute leukemias with specific genetic mutations. Revuforj, approved for two patient populations in 2024 and 2025, received the award alongside its recent expanded approval for acute myeloid leukemia (AML) with NPM1 m...
12-12 12:00
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Mizuho Upgrades Incyte to Outperform, Raises Price Target to $121
Mizuho analyst Salim Syed upgrades Incyte (NASDAQ:INCY) from Neutral to Outperform and raises the price target from $90 to $121.
12-08 21:47
FDA fast-tracks Incyte drug for rare blood cancer
Incyte (INCY) on Sunday said the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to INCA033989, an experimental antibody designed to treat patients with a specific genet...
12-07 23:31
Trevi Therapeutics appoints new CFO
Trevi Therapeutics (TRVI) named David Hastings as its next chief financial officer, effective January 6, 2026. Hastings prior roles include CFO positions at Arbutus, Unilife, and Incyte. Hastings curr...
12-04 20:43
